Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival

Overview

Journal Transl Oncol

Specialty Oncology

Date 2015 Oct 27

PMID 26500033

Citations 27

Authors

Jenny-Maria Jonsson

Nicolai Skovbjerg Arildsen

Susanne Malander

Anna Masback

Linda Hartman

Mef Nilbert

Ingrid Hedenfalk

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Although most ovarian cancers express estrogen (ER), progesterone (PR), and androgen (AR) receptors, they are currently not applied in clinical decision making. We explored the prognostic impact of sex steroid hormone receptor protein and mRNA expression on survival in epithelial ovarian cancer.

Methods: Immunohistochemical stainings for ERα, ERβ, PR, and AR were assessed in relation to survival in 118 serous and endometrioid ovarian cancers. Expression of the genes encoding the four receptors was studied in relation to prognosis in the molecular subtypes of ovarian cancer in an independent data set, hypothesizing that the expression levels and prognostic impact may differ between the subtypes.

Results: Expression of PR or AR protein was associated with improved 5-year progression-free (P=.001 for both) and overall survival (P<.001 for both, log-rank test). ERα and ERβ did not provide prognostic information. Patients whose tumors coexpressed PR and AR had the most favorable prognosis, and this effect was retained in multivariable analyses. Analyses of the corresponding genes using an independent data set revealed differences among the molecular subtypes, but no clear relationship between high coexpression of PGR and AR and prognosis.

Conclusions: A favorable outcome was seen for patients whose tumors coexpressed PR and AR. Gene expression data suggested variable effects in the different molecular subtypes. These findings demonstrate a prognostic role for PR and AR in ovarian cancer and support that tumors should be stratified based on molecular as well as histological subtypes in future studies investigating the role of endocrine treatment in ovarian cancer.

Citing Articles

Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities.

Dotto G, Buckinx A, Ozdemir B, Simon C Nat Rev Cancer. 2024; 25(2):93-108.

PMID: 39587300 DOI: 10.1038/s41568-024-00772-w.

CA-125:CA72-4 ratio - towards a promising cost-effective tool in ovarian cancer diagnosis and monitoring of post-menopausal women under hormone treatment.

Margoni A, Gargalionis A, Papavassiliou A J Ovarian Res. 2024; 17(1):164.

PMID: 39127704 PMC: 11316994. DOI: 10.1186/s13048-024-01487-0.

Steroid metabolism and hormonal dynamics in normal and malignant ovaries.

Beevors L, Sundar S, Foster P Essays Biochem. 2024; 68(4):491-507.

PMID: 38994724 PMC: 11625866. DOI: 10.1042/EBC20240028.

Advances in ovarian tumor stem cells and therapy.

Chen B, Liu J Cell Biochem Biophys. 2024; 82(3):1871-1892.

PMID: 38955927 DOI: 10.1007/s12013-024-01385-8.

Reevaluating the Role of Progesterone in Ovarian Cancer: Is Progesterone Always Protective?.

Mauro L, Spartz A, Austin J, Lange C Endocr Rev. 2023; 44(6):1029-1046.

PMID: 37261958 PMC: 11048595. DOI: 10.1210/endrev/bnad018.

References

Konecny G, Wang C, Hamidi H, Winterhoff B, Kalli K, Dering J . Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014; 106(10). PMC: 4271115. DOI: 10.1093/jnci/dju249. View

Arias-Pulido H, Smith H, Joste N, Bocklage T, Qualls C, Chavez A . Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol. 2009; 114(3):480-5. PMC: 2756056. DOI: 10.1016/j.ygyno.2009.05.045. View

Aghmesheh M, Edwards L, Clarke C, Byth K, Katzenellenbogen B, Russell P . Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. Gynecol Oncol. 2005; 97(1):16-25. DOI: 10.1016/j.ygyno.2004.12.030. View

Foulkes W, Metcalfe K, Sun P, Hanna W, Lynch H, Ghadirian P . Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004; 10(6):2029-34. DOI: 10.1158/1078-0432.ccr-03-1061. View

Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J . Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2012; 23(1):25-33. DOI: 10.1097/IGC.0b013e3182788466. View

Niwa K, Onogi K, Wu Y, Mori H, Harrigan R, Tamaya T . Clinical implication of medroxyprogesterone acetate against advanced ovarian carcinoma: a pilot study. Eur J Gynaecol Oncol. 2008; 29(3):252-5. View

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

Mohammed H, Russell I, Stark R, Rueda O, Hickey T, Tarulli G . Progesterone receptor modulates ERα action in breast cancer. Nature. 2015; 523(7560):313-7. PMC: 4650274. DOI: 10.1038/nature14583. View

Mason B, Holdaway I, Mullins P, Yee L, Kay R . Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res. 1983; 43(6):2985-90. View

10.

Winter 3rd W, Maxwell G, Tian C, Carlson J, Ozols R, Rose P . Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25(24):3621-7. DOI: 10.1200/JCO.2006.10.2517. View

11.

Zhong Q, Peng H, Zhao X, Zhang L, Hwang W . Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2014; 21(1):211-20. PMC: 4286460. DOI: 10.1158/1078-0432.CCR-14-1816. View

12.

Winter 3rd W, Maxwell G, Tian C, Sundborg M, Rose G, Rose P . Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 26(1):83-9. DOI: 10.1200/JCO.2007.13.1953. View

13.

Rocereto T, Saul H, Aikins Jr J, Paulson J . Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol. 2000; 77(3):429-32. DOI: 10.1006/gyno.2000.5789. View

14.

McDonnel A, Van Kirk E, Isaak D, Murdoch W . Inhibitory effects of progesterone on plasma membrane fluidity and tumorigenic potential of ovarian epithelial cancer cells. Exp Biol Med (Maywood). 2003; 228(3):308-14. DOI: 10.1177/153537020322800310. View

15.

Lee P, Rosen D, Zhu C, Silva E, Liu J . Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol. 2005; 96(3):671-7. DOI: 10.1016/j.ygyno.2004.11.010. View

16.

Smyth J, Gourley C, Walker G, Mackean M, Stevenson A, Williams A . Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res. 2007; 13(12):3617-22. DOI: 10.1158/1078-0432.CCR-06-2878. View

17.

Beral V, DOLL R, Hermon C, Peto R, Reeves G . Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008; 371(9609):303-14. DOI: 10.1016/S0140-6736(08)60167-1. View

18.

DAmico A, Chen M, Renshaw A, Loffredo M, Kantoff P . Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008; 299(3):289-95. DOI: 10.1001/jama.299.3.289. View

19.

Bowman A, Gabra H, Langdon S, Lessells A, Stewart M, Young A . CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002; 8(7):2233-9. View

20.

Wu X, Subramaniam M, Negron V, Cicek M, Reynolds C, Lingle W . Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody. J Cell Biochem. 2011; 113(2):711-23. PMC: 3725124. DOI: 10.1002/jcb.23443. View